Advance your academic career, collaborate globally, and expand your network— join now !

Dr. Guangdi Wang

RCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, Louisi...

Share Link

Share

Information

Guangdi Wang is a Professor of Chemistry in the Department of Chemistry, Xavier University of Louisiana. Wang obtained his PhD in Chemistry from the University of New Orleans in 1995 and joined Xavier University as a faculty in the same year. Guangdi Wang’s research has focused on the discovery of therapeutic targets by means of global proteomic analysis of diseased vs normal biospecimen and the development of small-molecule drugs for cancer treatment. His laboratory has designed, synthesized, and tested over three hundred novel chemical entities as selective estrogen receptor modulators (SERM) for breast cancer, anti-metastasis and vascular disrupting agents for solid tumor treatment. Several lead compounds are in various stages of pre-clinical studies. He is the Principal Investigator and Program Director of Xavier’s RCMI Cancer Research Center funded by NIH for the period of 2009 to 2019 with a total fund of over $20 million. Wang was the 2013 recipient of the Norman C. Francis Excellence in Research award for a senior faculty at Xavier University.

Research Keywords & Expertise

Design, synthesis, and...
Novel lead compounds o...
Novel lead compounds o...
SERMs that are not cro...
SERDs that are not cro...

Fingerprints

23%
Design, synthesis, and biological evaluation of SERMs and SERDs

Short Biography

Guangdi Wang is a Professor of Chemistry in the Department of Chemistry, Xavier University of Louisiana. Wang obtained his PhD in Chemistry from the University of New Orleans in 1995 and joined Xavier University as a faculty in the same year. Guangdi Wang’s research has focused on the discovery of therapeutic targets by means of global proteomic analysis of diseased vs normal biospecimen and the development of small-molecule drugs for cancer treatment. His laboratory has designed, synthesized, and tested over three hundred novel chemical entities as selective estrogen receptor modulators (SERM) for breast cancer, anti-metastasis and vascular disrupting agents for solid tumor treatment. Several lead compounds are in various stages of pre-clinical studies. He is the Principal Investigator and Program Director of Xavier’s RCMI Cancer Research Center funded by NIH for the period of 2009 to 2019 with a total fund of over $20 million. Wang was the 2013 recipient of the Norman C. Francis Excellence in Research award for a senior faculty at Xavier University.